PMVP

Pmv Pharmaceuticals Inc

PMVP.US pmvpharma.com
1.42
-0.02 (-1.39%)
USD · NASDAQ
52-week range
1.02
1.88
Trading at 47% of the 52-week range
Market Cap
74.84M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
1.34
Div. Yield
N/A
% Institutions
45.67%
% Insiders
2.37%

1 Year

+13.8%

3 Year

-78.1%

10 Year

-96.3%
Description

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.

Company Information

Company Name
Pmv Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US69353Y1038
CIK: 0001699382
CUSIP: 69353Y103
Currency: USD
Full Time Employees: 54
Phone: 609 642 6670
Fiscal Year End: December
IPO Date: Sep 25, 2020
Description:

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.

Address:

400 Alexander Park Drive, Princeton, NJ, United States, 08540

People

Directors & Officers

Name Title Year Born
Dr. David H. Mack Ph.D. Co-Founder, CEO, President & Director 1962
Dr. Arnold J. Levine Ph.D. Co-Founder, Independent Director & Member of Scientific Advisory Board 1940
Mr. Robert Ticktin J.D. General Counsel, COO & Company Secretary 1962
Dr. Deepika Jalota Pharm.D. Chief Development Officer 1977
Mr. Michael Carulli Chief Financial Officer 1974
Mr. Tim Smith M.B.A. Senior VP and Head of Corporate Development & Investor Relations NA
Ms. Crystal Zuckerman Vice President of Human Resources NA
Dr. Binh Vu Ph.D. Senior Vice President of Drug Discovery & CMC NA
Dr. Marc Fellous M.D. Senior VP and Head of Clinical Development & Medical Affairs NA
Ms. Laura De Leon VP & Head of Clinical Development Operations NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Oct 23, 2025 Orbimed Advisors Llc N/A Sale 1.00M $1.52 $1.52M
Sep 10, 2025 Orbimed Advisors Llc N/A Sale 500.00K $1.80 $900.00K
Jul 01, 2025 David Henry Mack N/A Sale 58.41K $1.06 $61.92K
Jul 01, 2025 Deepika Jalota N/A Sale 33.07K $1.06 $35.05K
Jul 01, 2025 Robert Ticktin N/A Sale 23.15K $1.06 $24.54K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BML Capital Management LLC 5.33M Jun 30, 2026 9.97% $4.06 0.19%
TANG CAPITAL MANAGEMENT LLC 4.25M Mar 31, 2026 7.94% $0.27 -14.07%
Sio Capital Management, LLC 2.63M Jun 30, 2026 4.93% $0.58 -14.38%
Euclidean Capital LLC 2.63M Jun 30, 2026 4.92% $0.80 0.00%
Adage Capital Partners Gp LLC 2.36M Jun 30, 2026 4.41% $0.00 26.88%
Acadian Asset Management LLC 2.22M Mar 31, 2026 4.15% $0.00 0.00%
Vanguard Capital Management, LLC 1.97M Mar 31, 2026 3.69% $0.00 0.00%
ArrowMark Colorado Holdings, LLC (ArrowMark Partners) 1.96M Jun 30, 2026 3.67% $0.11 -31.79%
Eversept Partners, LP 1.89M Jun 30, 2026 3.54% $0.13 -19.48%
Two Sigma Investments LLC 1.88M Mar 31, 2026 3.53% $0.00 166.91%
BlackRock Inc 874.37K Mar 31, 2026 1.64% $0.00 -20.14%
Morgan Stanley - Brokerage Accounts 864.31K Mar 31, 2026 1.62% $0.00 774.15%
Stonepine Capital Management Llc 708.10K Mar 31, 2026 1.32% $0.35 -38.47%
Longaeva Partners L.P. 552.03K Mar 31, 2026 1.03% $0.03 0.00%
Geode Capital Management, LLC 495.92K Mar 31, 2026 0.93% $0.00 11.16%
Aldebaran Capital LLC 473.36K Mar 31, 2026 0.89% $0.45 -0.97%
Marshall Wace Asset Management Ltd 434.09K Mar 31, 2026 0.81% $0.00 -6.66%
Bridgeway Capital Management, LLC 428.85K Mar 31, 2026 0.80% $0.01 0.00%
Verdad Advisers, LP 362.36K Jun 30, 2026 0.68% $0.47 101.13%
Walleye Trading Advisors, LLC 335.69K Mar 31, 2026 0.63% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 1.49M 2.79% ▲ 0.00% Jul 31, 2026
2 ArrowMark Small Cap Gro 1.06M 1.98% ▼ 2.06% Jun 30, 2026
3 Meridian Small Cap Growth Legacy 1.06M 1.98% ▼ 2.06% Jun 30, 2026
4 Vanguard Institutional Extnd Mkt Idx Tr 452.36K 0.85% ▲ 0.00% Jul 31, 2026
5 Bridgeway Ultra-Small Company 331.45K 0.62% ▲ 0.00% Jun 30, 2026
6 Fidelity Extended Market Index 215.53K 0.40% ▼ 0.19% Jul 31, 2026
7 iShares Micro-Cap ETF 159.47K 0.30% ▼ 1.95% Aug 31, 2026
8 Extended Equity Market Fund B 100.09K 0.19% ▲ 0.00% Dec 31, 2025
9 Blackrock Extended Mkt Fund CF 100.09K 0.19% ▲ 0.00% May 31, 2026
10 Extended Equity Market Fund E 100.09K 0.19% ▲ 0.00% Dec 31, 2025

Financial Highlights

Market Cap: $74.84M
EBITDA: $-79.54M
Book Value: $1.34
Earnings/Share: $-1.42
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -42.39%
ROE (TTM): -70.93%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $-3.30M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 53.46M
Shares Float: 48.41M
% Insiders: 2.37%
% Institutions: 45.67%
Short % Float: 4.39%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-133.00K
Gross Profit
subtotal
$-133.00K
SG&A
adjust
$-16.33M
R&D
adjust
$-69.88M
Operating Income
subtotal
$-86.21M
Other / Non-Operating Items
adjust
$8.46M
Net Income
subtotal
$-77.74M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about PMVP.US!